Medical technology - top companies based on revenue 2026

Leading medical technology companies worldwide based on revenue in 2026

Medtronic is the largest medical technology company in the world in 2026, with revenue of about 36.4 billion dollars. Johnson & Johnson MedTech follows on about 33.8 billion and Abbott on about 30.3 billion. The league table of the largest medical technology companies is one of the most closely watched rankings in healthcare, because the handful of giants at the top set prices, buy up innovation and largely determine which new technologies reach patients. On the 2026 figures, the top five are Medtronic about 36.4 billion dollars, Johnson & Johnson MedTech on 33.8 billion, Abbott on 30.3 billion, Medline Industries on 28.4 billion and Siemens Healthineers on 27 billion. What makes the 2026 edition of the ranking unusually interesting is that the order at the top, unchanged for a decade, is about to be decided not by sales performance but by a corporate restructuring already under way.

The top ten companies together generate about 264 billion dollars, roughly 40 percent of the global medical technology market. The ranking sits within our leading medical device companies and medical technology industry coverage.

Medtronic leads: Medtronic generated about 36.4 billion dollars in 2026, ahead of Johnson & Johnson MedTech on 33.8 billion, with every leading company growing on the year.

Medtronic recorded its strongest revenue growth in a decade, at about 8.4 percent, though the spin-off of its diabetes business could cost it the top spot, themes our medical devices revenue and medtech industry data coverage explores.

A note on the data. The figures show leading medical technology companies worldwide based on revenue in 2026, from company annual reports and industry rankings. Company definitions and fiscal years differ, so rankings vary between sources. Because some rankings count entire companies while others count only medical device segments, and because fiscal years end at different points, the same company can appear with revenue differing by ten billion dollars or more between sources. The ranking here covers medical technology, device and diagnostics revenue for the most recently completed fiscal year of each company, drawn from annual reports, regulatory filings and established industry rankings.

Largest Medical Technology Companies

The table shows the ten largest medical technology companies by revenue in 2026, alongside their 2025 figures and growth rates. It shows Medtronic leading, with Stryker and Boston Scientific the fastest growers. Reading down the growth column shows Boston Scientific about 12.3 percent and Stryker about 11.1 percent well ahead of the field, while Philips about 3.5 percent and GE HealthCare about 4.6 percent trail it. Because fiscal years end at different points and some figures are reported at group rather than segment level, the table is best read as a consistent snapshot of relative scale rather than a set of precisely comparable numbers. The market-share column is the most useful for putting the giants in perspective, since even the largest medical technology company in the world holds only about five and a half percent of its market, a far more fragmented picture than in most technology industries.

Which Is the Largest Medtech Company?

Medtronic leads the medical technology ranking in 2026 with about 36.4 billion dollars of revenue, ahead of Johnson & Johnson MedTech on about 33.8 billion, Abbott on 30.3 billion, Medline Industries on 28.4 billion and Siemens Healthineers on 27 billion. The order at the top of the ranking has been remarkably stable for a decade, dominated by the same American names, though the margins between them are far narrower than their reputations suggest. Medtronic about 36.4 billion dollars leads, ahead of Johnson & Johnson MedTech on about 33.8 billion, Abbott on 30.3 billion, Medline on 28.4 billion, Siemens Healthineers on 27 billion and Stryker on 25.1 billion. Scale in medical technology buys more than revenue, since the largest suppliers win the contracts, fund the biggest sales forces and can afford to lose money for years in a new category while smaller rivals cannot.

The scale of the leaders reflects decades of acquisitions and the advantage of breadth in an industry where hospitals increasingly prefer to buy from fewer, larger suppliers, a consolidation our medtech M&A coverage frames.

The top ten: Medtronic, Johnson & Johnson MedTech and Abbott lead the ranking, with eight of the ten largest medical technology companies based in the United States.

Behind the top five come Stryker on about 25.1 billion dollars, Becton Dickinson on 21.8 billion, GE HealthCare on 20.6 billion, Philips on 20.5 billion and Boston Scientific on 20.1 billion, with the ranking tightly bunched below third place. The tight bunching of the ranking below third place means that a single acquisition or divestiture can move a company several positions, which is exactly what the current wave of spin-offs is about to do. The tight bunching from sixth to tenth place, where barely five billion dollars separates the companies, means the lower half of the top ten reshuffles far more often than the top three.

Will J&J Overtake Medtronic?

The contest for the top spot is closer than it looks. Medtronic revenue of about 36.4 billion dollars is ahead of Johnson & Johnson MedTech on 33.8 billion, but the gap has narrowed sharply over the past five years as the challenger has grown faster. The rivalry for the title of largest medical technology company has become the defining contest in the industry, a slow-motion race in which the leader has been steadily reeled in by a challenger growing faster and buying more aggressively. Medtronic revenue grew from about 28.9 billion dollars in 2020 to 36.4 billion in 2026, while Johnson & Johnson MedTech grew from about 23 billion to 33.8 billion over the same period, closing the gap from nearly 6 billion to about 2.6 billion. The story of the past five years in medical technology has been the steady, patient closing of a gap that once looked unbridgeable, achieved less through spectacular growth than through relentless acquisition and disciplined execution.

Johnson & Johnson MedTech has grown through aggressive dealmaking, including the 13.1 billion dollar purchase of Shockwave Medical, a strategy our biggest companies by market value coverage frames.

The gap narrows: the Medtronic lead over Johnson & Johnson MedTech has shrunk from nearly 6 billion dollars in 2020 to about 2.6 billion in 2026.

The decisive factor may be the Medtronic decision to separate its diabetes business, MiniMed, which generated about 2.8 billion dollars a year and floated in February 2026 at a valuation near 7.9 billion, taking that revenue off the Medtronic books in time. The timing of the MiniMed separation makes the next ranking genuinely uncertain, since removing nearly three billion dollars of annual revenue would leave the two leaders separated by less than a single percentage point. Looking ahead, the next edition of the ranking is the one to watch, since it will be the first to reflect a full year without MiniMed revenue on the Medtronic books.

Which Company Is Growing Fastest?

Growth across the leading medical technology companies has been solid. Boston Scientific and Stryker grew fastest, at about 12 and 11 percent, while Medtronic grew about 8.4 percent, its best in a decade, and Philips grew most slowly at about 3.5 percent. Growth rates reveal far more about the health of each company than revenue alone, separating those winning share in the fastest-growing therapy areas from those defending mature positions in slower ones. Boston Scientific about 12.3 percent and Stryker about 11.1 percent grew fastest, ahead of Medtronic on about 8.4 percent, Becton Dickinson on 7.9 percent, Medline on 7.6 percent and Abbott on 7.1 percent. Growth rates in medical technology are usually clustered tightly in the mid single digits, which makes the current spread, from roughly three to twelve percent, unusually wide and genuinely informative about competitive position.

The fastest growers are those winning share in cardiology, structural heart and surgical robotics, the highest-growth corners of the industry, a pattern our medtech market by segment coverage frames.

Boston Scientific fastest: Boston Scientific grew about 12.3 percent and Stryker about 11.1 percent, while Philips grew about 3.5 percent.

The spread between the fastest and slowest growers, roughly nine percentage points, is wide for an industry often thought of as uniform, and reflects very different exposures to fast and slow-growing therapy areas. The wide spread of growth rates is a reminder that medical technology is not one market but many, and that a company fortunes depend far more on which therapy areas it serves than on the health of the industry as a whole. A company growing at twelve percent doubles in six years while one growing at three and a half percent takes twenty, which is why these apparently modest differences in growth rate reshape the ranking over time.

Where Are the Leaders Based?

American companies dominate the ranking. Eight of the top ten are based in the United States, accounting for about 82 percent of the revenue of the top ten, with German Siemens Healthineers on about 10 percent and Dutch Philips on about 8 percent. The national composition of the ranking is one of its most striking features, an overwhelming American dominance that reflects both the size of the United States healthcare market and its role as the launchpad for most new medical technology. The eight American companies generate about 216.5 billion dollars of the 264 billion top-ten total, or about 82 percent, against about 27 billion for German Siemens Healthineers and 20.5 billion for Dutch Philips. The dominance of American companies in medical technology is not merely a matter of home-market size, since it also reflects a regulatory system that most firms treat as the global gateway and a capital market that funds device innovation more generously than any other.

The American lead reflects the depth of the United States healthcare market, its research base and its role as the first market for most new devices, a concentration our medtech market by area coverage frames.

American dominance: United States companies account for about 82 percent of top-ten revenue, against 10 percent for Germany and 8 percent for the Netherlands.

The two European names in the top ten, Siemens Healthineers and Philips, both built their scale in medical imaging and hospital equipment, the areas where European medical technology has always been strongest. The enduring strength of the European names in imaging and hospital equipment reflects a history stretching back more than a century, and shows that scale in medical technology can be built outside the United States. The persistence of two European names in the top ten, both built on imaging and hospital systems, shows that the American advantage is real but not absolute, and that scale can still be built around a distinctive technical strength.

How Much of the Market Do They Hold?

The top ten medical technology companies generate about 264 billion dollars between them, roughly 40 percent of the 666 billion dollar global market. The top 100 companies account for about 487 billion dollars, or nearly three quarters of it. How much of the market the largest companies control is one of the more important structural questions in medical technology, shaping everything from hospital purchasing power to the prospects of the smaller firms trying to compete. The top ten about 264 billion dollars hold roughly 40 percent of the 666 billion dollar global market, the next ninety companies about 223 billion or 33 percent, and thousands of smaller firms share the remaining 27 percent. Concentration matters in medical technology because hospitals buy through group purchasing organisations that favour large, diversified suppliers, which means scale tends to reinforce itself once a company reaches the top tier.

The concentration at the top is high but stable, with the top-ten share hovering around 40 percent for years, a structure our medtech market worldwide coverage frames.

Top ten hold 40 percent: the ten largest companies generate about 40 percent of global medtech revenue, with the next ninety adding a further 33 percent.

Steady at 40 percent: the combined revenue of the top ten has grown from about 205 billion dollars in 2020 to 264 billion in 2026, holding around 40 percent of the market.

Below the giants sits a long tail of thousands of specialist manufacturers, many highly profitable in narrow niches, and it is from this tail that the largest companies buy most of their new technology. The long tail of specialist manufacturers is the research and development engine of the industry, and the flow of technology from that tail into the giants through licensing and acquisition is what keeps the leaders ahead. The relationship between the giants and the long tail is symbiotic rather than adversarial, since the small specialists supply the innovation and the giants supply the distribution, regulatory expertise and capital to scale it worldwide.

The Next Tier

Beyond the top ten, Roche Diagnostics is the largest company at about 17.3 billion dollars, followed by Baxter, Alcon, Danaher and Intuitive Surgical. The second tier includes some of the fastest-growing companies in the industry. The tier just below the top ten is where much of the dynamism of the industry sits, home to the fastest-growing specialists and the diagnostics leaders that a device-focused ranking can easily overlook. Roche Diagnostics about 17.3 billion dollars leads the second tier, ahead of Baxter on about 11.2 billion, Alcon on 10.6 billion, Danaher on 10.4 billion, Intuitive Surgical on 9.7 billion and Zimmer Biomet on 8.1 billion. The second tier of the ranking is where the industry future is most visible, since it contains both the diagnostics leaders that device rankings tend to overlook and the fast-growing specialists likely to enter the top ten within a few years.

Roche leads the diagnostics side of medical technology rather than devices, and its scale in testing puts it ahead of many better-known device makers, a split our in vitro diagnostics coverage frames.

Roche leads the tier: Roche Diagnostics is the largest company outside the top ten at about 17.3 billion dollars, ahead of Baxter, Alcon and Danaher.

Intuitive Surgical is the standout of the second tier, growing far faster than the giants on the strength of its dominance in surgical robotics, and it is closing on the top ten despite its much narrower focus. The rise of Intuitive Surgical from specialist to near-giant is the clearest evidence that focus can still beat breadth in medical technology, provided a company dominates a genuinely large and fast-growing category. Looking further down the list, the companies growing fastest are almost all specialists in robotics, structural heart and molecular diagnostics, the three areas where the industry expects the most growth this decade.

Why Do Medtech Rankings Differ?

Rankings of medical technology companies differ widely between sources, and the reason is definitional. Some count whole companies, others only device segments, and fiscal years end at different points, so the same company can appear with very different revenue. Anyone comparing medical technology rankings quickly runs into a frustrating problem, namely that no two lists agree, and the reason has far less to do with data quality than with the definitions each source chooses. The lack of a single agreed ranking is a genuine problem for anyone trying to understand the industry, and it means the sensible approach is to read any list alongside its definitions rather than treating the order as settled fact.

Abbott is the clearest example, appearing anywhere between about 21 and 30 billion dollars depending on whether diagnostics and nutrition are included, a definitional problem our medical technology market coverage frames.

Adding to 264 billion: Medtronic, Johnson & Johnson MedTech and Abbott contribute about 100 billion dollars of the 264 billion top-ten total between them.

Dialysis and healthcare services companies such as Fresenius Medical Care are large enough to rank near the top by revenue, but most device rankings exclude them because they are classified as service providers rather than manufacturers. The exclusion of dialysis and healthcare services companies from most device rankings is a defensible choice, but it means readers comparing lists should always check what each source has counted before drawing conclusions.

The Wave of Spin-Offs

Portfolio simplification is the strategic theme of 2026. Medtronic has separated MiniMed, Becton Dickinson is separating its diabetes care business, and Johnson & Johnson has been reported to be weighing options for its orthopedics unit DePuy Synthes. The strategic story of 2026 in medical technology is not expansion but subtraction, as the largest companies break themselves into more focused pieces in pursuit of faster growth and higher valuations. The current fashion for breaking up medical technology conglomerates marks a reversal of the strategy that built them, as companies that spent decades acquiring their way to scale now find investors rewarding focus instead.

The wave of separations reflects investor pressure to focus on higher-growth businesses, a pressure our Nasdaq stock market coverage frames through the listed companies making these decisions.

Every leader grows: between 2024 and 2026 every one of the largest companies increased revenue, with Stryker and Medtronic adding the most.

The effect on the rankings will be significant, since a company that spins off a multi-billion-dollar unit can fall several places, which is precisely what may hand the top spot to Johnson & Johnson MedTech. The coming reshuffle of the rankings will owe more to corporate restructuring than to any change in underlying performance, a reminder that league tables measure corporate structure as much as commercial success.

The Artificial Intelligence Race

Artificial intelligence is reshaping the competitive order. The largest companies are racing to embed algorithms in their devices, and the regulator has now authorised more than 1,300 AI-enabled devices, with a record 258 cleared in 2025 alone. Artificial intelligence has become the battleground on which the largest medical technology companies now compete, and the scale of the leaders gives them advantages in data and distribution that smaller rivals struggle to match. The contest over artificial intelligence in medical devices is not really about algorithms at all, but about data, regulatory experience and installed base, three things the largest companies already have in abundance.

The leaders in imaging, Siemens Healthineers, GE HealthCare and Philips, have moved fastest, adding AI to scanners and reading software, a shift our AI market size coverage frames.

The scale of the largest companies gives them an advantage in artificial intelligence, since training useful clinical algorithms requires vast amounts of data of the kind only a large installed base of devices can generate. The data advantage enjoyed by the largest companies is likely to reinforce their lead over time, since each generation of algorithms trained on their installed base makes their devices harder for smaller rivals to match. The regulatory record, with more than a thousand authorised artificial-intelligence devices and a record number cleared in a single recent year, shows how quickly the technology has moved from novelty to routine feature.

Largest Medtech Companies in Numbers

A few numbers capture the ranking. Medtronic leads on about 36.4 billion dollars, Johnson & Johnson MedTech follows on 33.8 billion, the top ten generate about 264 billion between them, and eight of the ten are American. These figures together map an industry whose commanding heights are held by a small group of very large American companies, growing steadily and now reshaping themselves through a wave of separations. The picture that emerges is of an industry both remarkably stable and quietly in flux, with the same names at the top for years yet the order among them about to change for reasons that have little to do with selling more.

The figures matter because the largest companies set the pace of the industry, and their scale shapes everything from pricing to which technologies reach patients, a link our exciting healthcare technology coverage explores.

Together these figures show a ranking led by Medtronic but under pressure, dominated by American companies, growing solidly across the board, and about to be reshaped by a wave of spin-offs. For now, the medical technology ranking stands as a portrait of a mature industry whose leaders are large, profitable and American, and whose order is about to be shuffled by their own restructuring.

Largest Medtech Companies: The Big Picture

Taken together, the leading medical technology companies of 2026 map an industry led by Medtronic and Johnson & Johnson MedTech, concentrated in the United States, a story our global pharmaceutical industry coverage sets in the wider healthcare context.

Whether Medtronic holds the top spot will depend on how quickly it absorbs the loss of MiniMed revenue, but for now it leads a ranking being reshaped faster by spin-offs than by organic growth, alongside the licensing tracked in our medtech R&D licensing coverage.

Frequently Asked Questions: Largest Medtech Companies